Today, Nessa Childers, MEP hosted the launch of the Manifesto of the European Alliance for Personalised Medicine in the European Parliament.
The Manifesto sets out both the opportunities and challenges of ‘a targeted approach to the prevention, diagnosis and treatment of disease based on an individual’s specific profile’ - what is known as personalised medicine.
Currently available treatments for disease have revolutionised health in Europe and beyond, but science has now brought healthcare to the brink of another major evolution.
By a combination of molecular medicine and computer technology, it is becoming possible for screening of patients, early treatment, or prevention to be calibrated precisely, to deliver with maximum effectiveness. With personalised medicine, healthcare services will ensure the right intervention to the right patient at the right time - improving patient outcomes, reducing the likelihood of adverse events, and cutting down unnecessary treatments.
And the precision that personalised medicine will bring creates good prospects for better use of resources. As the demand for healthcare rises and public financing comes under greater strain, personalised medicine can play a part in getting maximum value for spending on health.
The shift towards personalised medicine has already started in fields such as cancer and blood diseases, and new products are being designed to match the approach.
The EAPM Manifesto sets out the requirements to take advantage of the opportunities, which include:
Adapting the authorisation procedures for medicines to take account of the innovative clinical trial designs that personalised medicine will depend on.
Wider coordination on research in Europe through Horizon 2020, with better access to information for researchers, doctors, pharmacists and patients.
High-quality molecular testing facilities in Europe.
Closer regulatory links between diagnostics and treatment.
Rules on data protection that safeguard privacy while permitting scientific sharing of data.
Reimbursement of personalised medicines on the basis of their added value to healthcare systems.
Multi-disciplinary training for healthcare professionals in the new approaches of personalised medicine.
Wider awareness among patients and the public of the rationale and potential of personalised medicine.
Notes for editors
The European Alliance for Personalised Medicine brings together scientific, clinical, caring and training expertise in personalised medicine and diagnostics, across patient groups, academia, health professionals and industry, as well as relevant departments of the European Commission and the European Medicines Agency. It was launched in March 2012, as a response to the need for wider understanding of priorities and a more integrated approach among lay and professional stakeholders.
For more information, please contact:
Tel.: +32 (0)472 535 104